- Home
- GRAL vs KROS Comparison
GRAL vs KROS Comparison
Compare GRAL & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- KROS
- Stock Information
- Founded
- GRAL 2016
- KROS 2015
- Country
- GRAL United States
- KROS United States
- Employees
- GRAL N/A
- KROS N/A
- Industry
- GRAL
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- GRAL
- KROS Health Care
- Exchange
- GRAL NYSE
- KROS Nasdaq
- Market Cap
- GRAL 610.9M
- KROS 589.8M
- IPO Year
- GRAL N/A
- KROS 2020
- Fundamental
- Price
- GRAL $18.49
- KROS $11.41
- Analyst Decision
- GRAL Hold
- KROS Buy
- Analyst Count
- GRAL 2
- KROS 11
- Target Price
- GRAL $16.00
- KROS $45.33
- AVG Volume (30 Days)
- GRAL 967.8K
- KROS 2.0M
- Earning Date
- GRAL 02-15-2025
- KROS 02-26-2025
- Dividend Yield
- GRAL N/A
- KROS N/A
- EPS Growth
- GRAL N/A
- KROS N/A
- EPS
- GRAL N/A
- KROS N/A
- Revenue
- GRAL $117,669,000.00
- KROS $651,000.00
- Revenue This Year
- GRAL $32.48
- KROS $303.27
- Revenue Next Year
- GRAL $14.72
- KROS N/A
- P/E Ratio
- GRAL N/A
- KROS N/A
- Revenue Growth
- GRAL 111.83
- KROS 8037.50
- 52 Week Low
- GRAL $12.33
- KROS $9.78
- 52 Week High
- GRAL $24.92
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- KROS 22.44
- Support Level
- GRAL N/A
- KROS $9.78
- Resistance Level
- GRAL N/A
- KROS $11.63
- Average True Range (ATR)
- GRAL 0.00
- KROS 0.89
- MACD
- GRAL 0.00
- KROS 1.07
- Stochastic Oscillator
- GRAL 0.00
- KROS 23.61
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.